Amgen Bets On ChemoCentryx's Rare Disease Drug In $3.7 Billion Deal
Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand for its bone disease drug.
Amgen Adds Potential Blockbuster Drug With $3.7 Billion ChemoCentryx Deal
U.S. drugmaker Amgen Inc is buying ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders.
Biogen Leans On New Alzheimer's Drug To Calm Investor Worries
Biogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm.
J&J's Cancer Drug Sales Help Weather Hit From Stronger Dollar
Johnson & Johnson on Tuesday reported quarterly results that beat analysts' estimates on strong demand for cancer drug Darzalex and its COVID-19 vaccine, even as the company cut its full-year adjusted profit forecast due to a stronger dollar.
U.S. Deaths From Antibiotic Resistant 'Superbugs' Rose 15% In 2020
U.S. deaths from bacteria resistant to antibiotics, also known as 'superbugs', jumped 15% in 2020 as the drugs were widely dispensed to treat COVID-19 and fight off bacterial infections during long hospitalizations, enabling the bugs to evolve, a U.S.
Explainer-What To Know About COVID Vaccines For Small Children
Advisers to the U.S. Food and Drug Administration are due to meet in June to decide on whether to recommend authorizing Moderna Inc's vaccine for children below 6 years old, and Pfizer Inc and BioNTech SE's COVID-19 vaccine for children below 5 years old.
Pfizer's $11.6 Billion Biohaven Buy Could Spark More Biotech Deals
Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.
U.S. FDA Advisers To Discuss Additional COVID Vaccine Shots, Booster Design
The U.S. Food and Drug Administration's expert advisers will discuss the timing of additional COVID-19 vaccine boosters and the people eligible for the extra shots in a meeting later this week, the health agency said on Monday.
Analysis-Drugmakers Look To Help Ukrainians In Drug Trials After Russian Invasion
The Russian invasion of Ukraine has left drugmakers scrambling to find ways for patients enrolled in clinical trials there to receive their medicines as millions seek shelter from bombardment and flee to neighboring countries.
Alibaba Co-Founder Jack Ma To Retire
Alibaba Group Holding Ltd’s co-founder and executive chairman, Jack Ma, will retire from the e-commerce company on Monday, as the former English teacher seeks to focus on philanthropy in education, the New York Times reported.
